Vor Biopharma Inc (VOR) Q3 2024 Earnings Report

Vor Biopharma remains in its clinical-stage, pre-revenue phase, executing on its VOR33 engineered hematopoietic stem cell program while incurring ongoing R&D-driven cash burn. For QQ3 2024 (fiscal Q3 2024), the company reported no revenue and a sizable operating loss driven by R&D and general/admin expenses. Net income amounted to a loss of approximately $27.56 million, with an EPS of -$0.40, and EBITDA of -$27.66 million. Cash burn from operating activities was about $23.3 million, contributing to a year-to-date cash balance of roughly $55.2 million at quarter-end, well below peak liquidity but adequate for near-term funding needs if the company secures additional financing or partnerships.

The balance sheet shows a conservative liquidity profile with cash and cash equivalents around $52.8 million and short-term investments of about $10.0 million, totaling roughly $62.8 million in readily marketable liquidity. Long-term debt remains modest (~$28.7 million), and net debt sits negative due to cash on hand, suggesting a cushion against near-term liquidity shocks provided financing remains available. The current ratio (~4.69) and cash ratio (~3.68) indicate solid short-term liquidity relative to current liabilities, though the runway is limited by the quarterly burn rate. Management commentary (not captured in the provided transcript) is expected to emphasize progress in VOR33 preclinical/early clinical activities, manufacturing readiness, and strategic partnerships to de-risk funding needs.

Overall, the QQ3 2024 quarter underscores the typical profile of a late-stage pre-revenue biotech: meaningful scientific progress and an attractive long-term addressable market, offset by a substantial near-term cash burn and a need for external financing to sustain operations until product-readout milestones or partnering events materialize.